Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28766149 | 0.82 | SLC6A2 (0.31) | SLC6A2TAAR1 | |
| SCHEMBL49872 | 0.80 | ALDH1A1 (0.32) | — | |
| SCHEMBL1503381 | 0.80 | ALDH1A1 (0.30) | — | |
| SCHEMBL9214276 | 0.78 | — | — | |
| SCHEMBL19405600 | 0.78 | TAAR1 (0.30) | TAAR1 | |
| SCHEMBL28470907 | 0.78 | ALDH1A1 (0.31) | — | |
| SCHEMBL8133491 | 0.76 | ALDH1A1 (0.30) | — | |
| SCHEMBL10631014 | 0.76 | — | — | |
| SCHEMBL454837 | 0.76 | — | — | |
| SCHEMBL7531243 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 199 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10294260-B2 | Tetracyclic anthraquinone derivatives | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2019-05-21 | — | — | US | claimed |
| US-20190071416-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2019-03-07 | — | — | US | claimed |
| EP-3371151-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | Agency For Science, Technology And Research (SG) | 2018-09-12 | — | — | EP | claimed |
| US-20170247403-A1 | TETRACYCLIC ANTHRAQUINONE DERIVATIVES | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO LTD (CN) | 2017-08-31 | — | — | US | claimed |
| US-9670242-B2 | Tetracyclic anthraquinone derivatives | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2017-06-06 | — | — | US | claimed |
| EP-2824108-B1 | TETRACYCLIC ANTHRAQUINONE DERIVATIVES | TIANJIN HEMAY BIO-TECH CO LTD (CN) | 2017-04-19 | — | — | EP | claimed |
| WO-2017061957-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-04-13 | — | — | WO | claimed |
| US-20150166595-A1 | Tetracyclic Anthraquinone Derivatives | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2015-06-18 | — | — | US | claimed |
| CN-104507912-A | (aza-)isoquinolinone derivatives | MERCK PATENT GMBH | 2015-04-08 | — | — | CN | claimed |
| EP-2824108-A1 | TETRACYCLIC ANTHRAQUINONE DERIVATIVES | Tianjin Hemay Bio-Tech Co., Ltd. (CN) | 2015-01-14 | — | — | EP | claimed |
| CN-104169284-A | Bicyclic pyrazinone derivatives | MERCK PATENT GMBH | 2014-11-26 | — | — | CN | claimed |
| US-5616711-A | REACTING BUTENE DERIVATIVE TO AN AMIDE DERIVATIVE; USEFUL AS INTERMEDIATES FOR PRODUCING ANTIULCER DRUGS | FUJIREBIO INC. (JP) | 1997-04-01 | — | — | US | claimed |
| EP-0582304-A2 | Methods of producing amino butene derivatives | FUJIREBIO Inc. (JP) | 1994-02-09 | — | — | EP | claimed |
| US-4828771-A | POLYEPOXIDES | TOTO LTD. (JP) | 1989-05-09 | — | — | US | claimed |
| US-4276295-A | VASODILATORS, HYPOTENSIVE, ANTIATHEROSCLEROTIC | Ishikawa, Masayuki (JP) | 1981-06-30 | — | — | US | claimed |
| CN-107690434-B | Fused tricyclic imidazopyrazine derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2021-07-30 | — | — | CN | disclosed |
| CN-105829307-B | Tetrahydroimidazopyridine derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2020-07-24 | — | — | CN | disclosed |
| US-5616711-A | REACTING BUTENE DERIVATIVE TO AN AMIDE DERIVATIVE; USEFUL AS INTERMEDIATES FOR PRODUCING ANTIULCER DRUGS | FUJIREBIO INC. (JP) | 1997-04-01 | — | — | US | disclosed |
| EP-0584192-A1 | PRODRUG ESTERS OF PHENOLIC 2-PIPERIDINO-1-ALKANOLS | PFIZER INC. (US) | 1994-03-02 | — | — | EP | disclosed |
| EP-0582304-A2 | Methods of producing amino butene derivatives | FUJIREBIO Inc. (JP) | 1994-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190071416-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | SMYD3, SMYD2, EHMT1 | SLC6A2 1484/4885TAAR1 3566/4885 |
| US-20150166595-A1 | Tetracyclic Anthraquinone Derivatives | ANTXR2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TBXA2R | SLC6A2 3352/4885TAAR1 980/4885 |
| US-10294260-B2 | Tetracyclic anthraquinone derivatives | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, F12, ANTXR2 | SLC6A2 3262/4885TAAR1 1397/4885 |
| US-20170247403-A1 | TETRACYCLIC ANTHRAQUINONE DERIVATIVES | ANTXR2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TBXA2R | SLC6A2 3352/4885TAAR1 980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.